Ładuje się......
EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
An increasing number of innovative oncology monoclonal antibodies (mAbs) have been introduced into the global market, and biosimilar versions have now also been approved in Europe. Being complex to develop and difficult to manufacture, the biosimilar is a drug similar but not identical in physicoche...
Zapisane w:
| Wydane w: | Int J Clin Pharm |
|---|---|
| Główni autorzy: | , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Springer International Publishing
2018
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6132979/ https://ncbi.nlm.nih.gov/pubmed/30094558 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11096-018-0709-6 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|